FDA panel asks for more data on Clovis' lung cancer drug

April 12, 2016 4:19 PM

16 0

An independent panel of experts to the U.S. Food and Drug Administration on Tuesday asked Clovis Oncology Inc for more data on its lung cancer drug before making a final decision on the treatment.

The drug, rociletinib, is designed to treat a subset of patients with advanced non-small cell lung cancer whose condition has worsened despite treatment.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page